Mechanisms and Duration of Immunity to SARS-CoV-2
- Funded by National Institutes of Health (NIH)
- Total publications:1 publications
Grant number: 1U54CA260517-01
Grant search
Key facts
Disease
COVID-19Start & end year
20202022Known Financial Commitments (USD)
$4,017,422Funder
National Institutes of Health (NIH)Principal Investigator
Scott Dexter BoydResearch Location
United States of AmericaLead Research Institution
Stanford UniversityResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Immunity
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Unspecified
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Other
Occupations of Interest
Unspecified
Abstract
OVERALL: Summary: We propose the Stanford U54 SARS-CoV-2 Serological Sciences Center of Excellence (SUSS-COE) as amember of the SeroNet consortium gathered to address the urgent need for better understanding of human immune responses to the SARS-CoV-2 coronavirus pandemic that has engulfed the U.S. and the world.Our Center will be based on four scientific pillars: Deep mechanistic analysis of the adaptive immune responses of COVID-19 patients, spanning serological, B cell and T cell responses, Analysis of immune responses in the blood as well as mucosal sites, Comparing immune responses induced by infection to those induced by candidate vaccines, and Studying medically underserved, underrepresented and at-risk patient populations Within these parameters, we will attempt to determine the factors that result in effective and durable immunity to SARS-CoV-2 infection.We are dedicated to broad collaboration, rapid sharing of data and technical knowledge, nimbleness in responding to the rapidly changing pandemic, and rapid translation of research findings to CLIA Lab clinical testing and development of new therapeutic approaches. We feel these are the best routes forward for addressing gaps in our understanding of the determinants of protective immunity to SARS-CoV-2, and providing useful tools for physicians and patients.
Publicationslinked via Europe PMC
Last Updated:2 days ago
View all publications at Europe PMC